# Disc Medicine Inc. (IRON) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $79.23, market value $3.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Disc Medicine Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.5%** (5-yr avg -51.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -28.7%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -51.8%**. Earnings per share fell 51.8%.

## Financial health
- **Debt to equity: 0.04**. Debt is 0.04 times equity: a conservative balance sheet.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Disc Medicine Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Disc Medicine Inc.; the consensus is strong_buy, with an average price target of $102.58 (+29% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.6%** (YTD -0.2%, 3-mo 18.3%). The shares are up 31.6% over twelve months including dividends.
- **From 52-week high: -20.4%** (98.1% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.79** (volatility 53%). Beta of 0.79 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IRON · Page: https://foliofundamentals.com/stocks/iron

Not investment advice.